PTO/SB/21 (04-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL **FORM**

(to be used for all correspondence after initial filing)

Alexandria, VA 22313-1450 on the date shown below.

Maureen K. Fitzpatrick

Typed or printed name

Total Number of Pages in This Submission

Application Number 10/771,046 February 3, 2004 Filing Date First Named Inventor Hague Art Unit 1615 **Examiner Name** Unknown **CP246** Attorney Docket Number

ENCLOSURES (check all that apply)						
Fee Transmittal F	om	☐ Drawing(s)	After Allowance Communication to Technology Center (TC)			
Fee Attached		Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences			
Amendment / Rep	oly	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)			
After Final		Petition to Convert to a Provisional Application	Proprietary Information			
Affidavits/dec	laration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter			
Extension of Time	e Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):			
Express Abandonment Request		Request for Refund CD, Number of CD(s)	1449 & 6 References			
Information Disclo	sure Statement					
Certified Copy of Priority Document(s)		Remarks				
Response to Missing Parts/ Incomplete Application						
Response to Missing Parts under 37 CFR 1.52 or 1.53						
	SIGNA	TURE OF APPLICANT, ATTORNEY, O	R AGENT			
Firm or Individual name Scott K. Larsen, Registration No. 38,532						
Signature	Signature / cooling					
Date	September 9, 2004					
CERTIFICATE OF TRANSMISSION/MAILING						

Signature This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, process) an application. Confidentially is governed by 35 0.5.0. 122and 37 or in 1.14. This confection is estimated to Complete, including gathering preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

September 9, 2004

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450,

SEP 1 3 2004 IN THE UNITED S

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Hague et al.

Confirmation No.: 2324

Serial No.: 10/771,046

Group Art Unit.: 1615

Filing Date: February 3, 2004

Examiner: Unknown

For.: SUGAR-FREE ORAL TRANSMUCOSAL SOLID DOSAGE FORMS AND

USES THEREOF

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

DATE OF DEPOSIT: SEPTEMBER 9, 2004
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE
INDICATED ABOVE AND IS ADDRESSED TO THE
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VA 22313-1450.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F. R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as a representation that a search has been made or an admission that this information is material to the patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above-identified application as set forth in § 1.491, or before the mailing date of a first Office Action on the merits of the above-identified application. No additional fee is required.

A copy of each cited non-US patent reference is enclosed.

Please charge any deficiency or credit any overpayment to Deposit Account No. 03-1195.

Date: September 9, 2004

Scott K. Larsen Attorney for Applicant Registration No. 38,532

CEPHALON, Inc. 145 Brandywine Parkway West Chester, PA 19380 Telephone: (610) 738-6463 Facsimile: (610) 738-6590



FO	ORM PTO-1449	Attorney Docket	CP246
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/771,046
		T 111	February 3, 2004
	CD	First Named Inventor	Hague et al.
List of Patent and Publications Cited by Applicant		Group Art Unit	1615
		Examiner Name	Unknown
		Sheet	1 of 2

Examiner	Cite	Document	Name	Date of	Class	Subclass
Initials	No.	Number	0.1	Publication	_	
	A1	2002/0106407	Coleman et al.	08/08/02	_	
	A2_	2002/0160043	Coleman	10/31/02	_	
	A3	4,671,953	Stanley et al.	06/09/87		
	A4	4,863,737	Stanley et al.	09/05/89		
	A5	5,132,114	Stanley et al.	07/21/92		
	A6	5,288,497	Stanley et al.	02/22/94		
	A7	5,288,498	Stanley et al.	02/22/94		
	A8	5,785,989	Stanley et al.	07/28/98		
	A9	6,264,981	Zhang et al.	07/24/01		
	A10	6,555,581	Franz et al.	04/29/03		
	A11	6,680,071	Johnson et al.	01/20/04		
Examiner	Cite N		IGN PATENT D	OCUMENTS		Translation
Initials	B6	WO 00/515	39 9/8/00	WIPO	· · · · · · -	YES NO

	OTHER DOCUMENTS Non-Patent Literature Documents				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), Title of Article, Title of Journal (book, magazine, catalog, etc.) Date, Pertinent Pages, Volume-Issue Number, publisher, city and/or country where published.			
	C1	Maland et al., "The Effects of Buffered Dosage Forms on the Pharmacokinetics and Bioavailability of Oral Transmucosal Fentanyl Citrate in Dogs", Pharmaceutical Research, Vol. 10, 1993, S-203, PDD7113 (abstract).			
	C2	Zhang et al., "Buccal Mucosal Absorption of Esmolol in an In Vivo Dog Model", Pharmaceutical Research, Vol. 9, 1992, S-177, PDD7035 (abstract).			

	<u> </u>		
Examiner's Signature	 	Date:	

FORM PTO-1449	Attorney Docket	CP246
INFORMATION DISCLOSURE	Application Number	10/771,046
STATEMENT BY APPLICANT	Filing Date	February 3, 2004
Vice CD and A D I II also Challe	First Named Inventor	Hague et al.
List of Patent and Publications Cited by Applicant	Group Art Unit	1615
rippiicum	Examiner Name	Unknown
	Sheet	2 of 2

C3	Zhang et al., "Estimation of Buccal Fentanyl Absorption Bioavailability by Measuring Drug Depletion From Vehicle Solutions: Validation of the Method in Dogs", Pharmaceutical Research, Vol. 9, 1992, S-177, PDD7034 (abstract).
C4	Maland et al., "Studies of the Bioavailability of Buccally Administered Etomidate in Dogs", Pharmaceutical Research, Vol. 10, 1993, S-202, PDD711 (abstract).
C5	Zhang et al., "Buccal Absorption Kinetics of Etomidate From a Solid Dosage Form in Dogs: A Deconvolution Analysis", Pharmaceutical Research, Vol. 10, 1993, S-202, PDD7112 (abstract).

	<u> </u>		
Examiner's Signature		Date:	